You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復必泰二價疫苗獲認可在港作緊急使用
阿思達克 11-18 11:34
政府公佈,醫務衛生局局長根據《預防及控制疾病(使用疫苗)規例》(第599K章),認可復星醫藥/德國藥廠BioNTech的復必泰原始株/Omicron變異株BA.4-5二價疫苗在香港作緊急使用。 醫務衛生局局長經參考顧問專家委員會的意見,並考慮新冠肺炎對公衆健康構成的威脅,認爲有關認可屬必要,並且符合公衆利益,已行使《規例》第3條所賦予的權力,認可復必泰二價疫苗在香港作指明目的。爲確保有關疫苗持續安全、有效及具品質保證,醫務衛生局局長對上述認可附加條件,包括要求申請人繼續提交該疫苗的最新臨牀數據、安全更新報告、藥廠生產每批疫苗的品質證明文件等。 根據藥廠提供的資料,首批供港復必泰二價疫苗預計可於本月底由德國運抵香港。政府接收到有關疫苗並完成必須的質檢程序後,會盡快爲市民提供有關疫苗,詳情稍後公佈。 政府發言人指出,除了50歲或以上人士應接種第四劑疫苗,18至49歲人士經考慮對自身的風險和益處,亦可選擇接種第四劑。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account